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An empirical evaluation of the SF-12, SF-6D,
EQ-5D and Michigan Hand Outcome
Questionnaire in patients with rheumatoid
arthritis of the hand
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Abstract
Background: The aim of this study was to assess the psychometric properties, namely acceptability, validity,
reliability, interpretability and responsiveness of the EuroQol EQ-5D (EQ-5D visual analogue (VAS) and EQ-5D (utility))
, Short Form 12 Dimensions (SF-12), SF-6D and Michigan Hand Outcome Questionnaire (MHQ) in patients with
rheumatoid arthritis (RA) of the hand.
Methods: The empirical investigation was based upon data from a randomised controlled trial of 488 adults with
rheumatoid arthritis who had pain and dysfunction of the hands and/or wrists. Participants completed the EQ-5D,
SF-12 and MHQ at baseline and at 4 and 12 months follow up. Acceptability was measured using completion rates
over time; construct validity using the “known groups” approach, based on pain troublesomeness; convergent
validity using spearman’s rho correlation (ρ); reliability using internal consistency (Cronbach’s alpha); interpretability
using minimal important differences (MID); and responsiveness using effect sizes and standardised response means
(SRM) stratified by level of self-rated improvement in hand and wrist function or level of self-rated benefit and
satisfaction from trial treatments.
Results: At baseline, the study population had a mean age of 62.4 years, a mean MHQ score of 52.1 and included
76% women. The EQ-5D (utility) had the highest completion rates across time points. All instruments discriminated
between pre-specified groups based on pain troublesomeness. Convergent validity analysis indicated that the MHQ
score correlated strongly with the EQ-5D (ρ = 0.65) and SF-6D (ρ = 0.63) utility scores. The MHQ was most
responsive at detecting change in indicators of RA pain severity between baseline and 4 months, whilst minimal
important differences varied considerably across PROMs.
Conclusions: The instruments evaluated in this study displayed varying psychometric properties in the context of
RA of the hand. The selection of a preferred instrument in evaluative studies should ultimately depend on the
relative importance placed on individual psychometric properties and the importance placed on generation of
health utilities for economic evaluation purposes.
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Background
Rheumatoid arthritis (RA) is a chronic and unpredict-
able disorder that can cause persistent joint pain, joint
damage and long-term disability (especially in the hands
and feet). The economic cost of RA is substantial for in-
dividual patients, health services and society as a whole
[1]. Patients with poor and declining function from their
diagnosis of RA generate elevated medical care costs [2].
A report by the National Rheumatoid Arthritis Society
(NRAS) in 2010 found that the overall cost of RA to the
UK economy was almost £8 billion per annum with Na-
tional Health Service (NHS) expenditure totalling ap-
proximately £700 million per annum [3].
Patient reported outcome measures (PROMs) are in-
creasingly used to measure health-related quality of life
(HRQoL) from the patient perspective. PROMs have also
increasingly been used in randomised controlled trials
(RCTs) and other evaluative studies to measure the ben-
efits of interventions in terms of health status or
HRQoL. PROMs can be condition-specific or generic.
Generic PROMs can either be preference-based (patient
responses are generally used to generate profile scores,
which are converted into index scores based on prefer-
ences for a given health state) or non-preference based
(patient responses are generally summed to provide a
score) with examples of the former such as the EQ-5D
and SF-6D offering several advantages [4, 5]. The main
advantages of generic preference-based PROMs are their
ease of administration and high rate of completion, the
generalizability of their results and their ability to meet
the requirements of decision-making bodies, such as the
National Institute for Health and Care Excellence
(NICE) in England and Wales, concerned with cost-
effectiveness comparisons [6]. Furthermore, preference-
based outcome measures can incorporate the impact of
treatment or ill health within multidimensional scales
and can be combined with data on survival in the
form of quality-adjusted life years (QALYs) [4]. Given
the increasing diffusion of PROMS within evaluative
research and the increasing use of the outputs of
preference-based outcome measures within decision-
making processes, it is important to establish the rela-
tive merits of alternative PROMS in specific clinical
and research contexts.
To be useful in assessing HRQoL in individuals with
RA of the hand, PROMS should satisfy a range of psy-
chometric properties. The psychometric literature has
developed a number of criteria to judge the performance
of different instruments, key to which are acceptability,
validity, reliability, interpretability and responsiveness to
changes in health state. Although the construct validity
of the EQ-5D has been investigated in the context of RA
[7] and the responsiveness of the EQ-5D and SF-6D in
patients with early arthritis [8], only one previous study
has compared the psychometric properties of generic
HRQoL measures (HUI2, HUI3, SF-6D and EQ-5D) with
a disease-specific instrument (Rheumatoid Arthritis
Quality of Life Scale, RAQoL) in the RA context [9].
The Michigan Hand Outcome Questionnaire (MHQ) is
a well-established measure for patients with RA and
widely used in clinical trials [10]. It has previously been
compared to the Health Assessment Questionnaire
(HAQ) in patients with RA [11] and also compared to
the SF-12 in a study including patients with thumb
osteoarthritis [12]. However, no studies have, to our
knowledge, have so far investigated the performance of
the MHQ in relation to preference-based measures..
The current study aims to fill this research gap by in-
vestigating the psychometric properties and performance
of generic PROMs compared to the MHQ for patients
with RA of the hand. It is anticipated that the results will
provide evidence for the use of generic (EQ-5D, SF-12,
SF-6D) and condition-specific PROMs in future research
studies, including economic evaluations, related to RA.
Methods
SARAH trial
The SARAH trial was a pragmatic, multi-centre, rando-
mised controlled trial conducted with 1 year follow-up.
488 participants with RA who had pain and dysfunction
of the hands and/or wrists were randomised to either a
tailored exercise programme in addition to usual care (n
= 246) or to usual care alone (n = 242).
The primary method of data capture was face-to-
face research clinic appointment.. Baseline and follow-
up data at 4 and 12 months after randomisation was
collected, including the MHQ score, EQ-5D utility,
EQ-5D VAS, SF-12 and SF-5D at each of these time
points.. Further details about the SARAH trial, its
sampling procedures, methodology, outcome measures
and responses rates are reported in full elsewhere
[13]. Since we were primarily interested in the prop-
erties of the outcome measures used, rather than any
evaluation of the interventions in the trial, all SARAH
participants were included in the analyses reported
here, regardless of trial allocation. The SARAH trial
was approved by the Oxford C Multicentre Research
Ethics Committee in June 2008.
Patient reported outcome measures
MHQ
The primary outcome measure for the SARAH study
was the MHQ overall hand function score at 12 months.
The MHQ is a common hand-specific outcome meas-
urement tool for patients with chronic hand conditions
[14]. The MHQ has been validated for use in a wide
range of patient samples. More specifically, it has been
used in carpal tunnel syndrome [15, 16], distal radius
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fracture [17], reconstruction [18, 19] and arthroplasty in
RA [20, 21]. The MHQ is appropriate for use in RA
populations due to the comprehensive information gath-
ered on functional abilities as well as patient satisfaction,
pain and hand appearance. It has been utilised to assess
disability and it is often an outcome measure for clinical
trials in RA. It measures patient perception of hand
function, appearance, pain, and satisfaction. It is
intended for people with hand or wrist conditions or in-
juries [14]. It can be used to measure a patient’s general
hand function, or can be used to assess changes in hand
function over time, e.g. pre- and post-operation. It con-
sists of 37 items and 6 subscales: overall hand function,
activities of daily living (ADL), pain, work performance,
aesthetics, and patient satisfaction with hand function.
Scores range from 0 to 100, with higher scores indicat-
ing better performance, except for the pain scale. For the
pain scale, a higher score indicates more pain [14].
EQ-5D
The EQ-5D-3L [22] (hereafter EQ-5D for brevity) com-
prises two components that assess health status on the
day of completion. The first component is a self-
reported descriptive system with five health dimensions
(mobility, self-care, pain/discomfort, usual activities, and
anxiety/depression) each divided into three different
levels, namely no problems, some or moderate problems
and severe or extreme problems. Responses to the de-
scriptive system are generally valued using the time-
trade method. For the purposes of this study, we applied
the York A1 (Dolan) tariff set derived from a survey of
the UK general population (n = 3337), which used the
time trade-off valuation method to estimate utility scores
for a subset of 45 EQ-5D health states, with the remain-
der of the EQ-5D health states subsequently valued
through the estimation of a multivariate model [23].
Resulting utility scores range from -0.59 to 1.0, with 0
representing death and 1.0 representing full health, with
some health states considered worse than death (<0). A
further component of the EQ-5D consists of a visual
analogue scale (VAS), which asks people to rate their
current overall health on a scale from 0 (the worst
health state they can imagine) to 100 (the best health
state they can imagine).
SF-12 and SF-6D
The SF-12 consists of 12 items that assess 8 dimensions
of health: physical functioning, role-physical, bodily pain,
general health, vitality, social functioning, role-emotional
and mental health. The SF-12 was scored as described
by Ware [24]. The SF-12 measures various aspects of
physical and mental health from which physical and
mental summary scores can be calculated. The Physical
Component Summary Score (PCS) and Mental Health
Component Score (MCS) are both standardised to have
a mean of 50 and a standard deviation of 10 [13].
A derivative of the SF-12 is the SF-6D, which is a
multi-attribute utility measure composed of 6 dimen-
sions (physical functioning, role limitation, social func-
tioning, pain, energy, mental health), each of which has
between four to six levels. The SF-6D generates 18,000
possible health states. To estimate health utilities for the
SF-6D, we applied an algorithm developed by Brazier
and colleagues [5] who surveyed a representative sample
of the UK general population using the standard gamble
technique. Utility values for SF-6D health states can fall
between 0.30 and 1.0, where 1.0 represents full health
and 0 represents death.
Indicators of RA pain
In the SARAH trial, RA pain was measured using the
Troublesomeness questionnaire (range 0-20, higher
score indicates greater pain) [25] at baseline, and at 4
and 12 months post-randomisation.
Statistical analysis
We followed the definitions and recommendations from
the COSMIN (Consensus-based Standards for the selec-
tion of health Measurement Instruments) checklist [26],
alongside a previously published checklist of assessment
criteria for PROMs [27], when analysing the psychomet-
ric properties of the MHQ, EQ-5D (utility) (preference-
based responses to the EQ-5D descriptive system), EQ-
5D (VAS), SF-12 and SF-6D in the SARAH trial. Statis-
tical analysis was conducted using STATA version 13.0
(Stata Corporation, Texas, USA) [28].
Acceptability
A PROM must be practical and acceptable to the popu-
lation that will be completing the instrument and also
represent the interests and perspectives of many differ-
ent individuals associated with the PROM. The accept-
ability of the different study PROMs was measured
using completion rates at baseline and each of the two
follow up time points (4 and 12 months post randomisa-
tion) [29, 30].
Validity
The validation process for PROMs aims to establish
whether a measure is useful in reaching the objective it
has been developed for. The overall validity of an instru-
ment is composed of a number of important compo-
nents, such as content, construct and criterion validity.
From a theoretical point of view a perfect validation
process would compare the outcomes of the examined
instrument to an external “gold standard”. However, for
a number of abstract constructs such as pain, happiness
or HRQoL, an external gold standard does not exist.
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This has led to the development of indirect empirical
tests of validity [31]. Although many different indirect
empirical tests of validity have been proposed in the so-
cial science literature, we focussed on construct and
convergent validity..
Construct validity concerns the degree to which the
scores of an instrument are an adequate reflection of the
dimensionality of the construct to be measured [26].
The construct validity of the instruments used in the
SARAH trial was assessed by the “known groups” ap-
proach [32]. In known groups validity, we take pre-
specified groups where we would expect there to be a
difference in health status, and thus instrument scores.
The different scores between groups for alternative mea-
sures can then be compared to see if there is a pattern
in the sensitivity to these expected differences [33]. Inde-
pendent samples t-tests were performed to estimate the
ability of each summary score, i.e. MHQ), EQ-5D (util-
ity), EQ-5D (VAS), SF-12 (PCS), SF-12 (MCS) and SF-
6D utility, to discriminate between groups with different
RA severity at baseline. RA pain severity was measured
using the Troublesomeness questionnaire () [25].We
classified individuals according to their pain trouble-
someness using a 30% threshold (low: pain troublesome-
ness score <30%; high: pain troublesomeness ≥30%) [25].
To assess convergent (discriminant) validity we assessed
the relationship between continuous clinical (MHQ))
and health-related utility measures (EQ-5D utility, SF-
6D utility) at baseline with the Spearman’s rank correl-
ation coefficient. A correlation coefficient between 0.9
and 1.0 suggests that variables can be considered very
highly correlated. Correlation coefficients between 0.7
and 0.9 indicate variables that can be considered
highly correlated. Correlation coefficients between 0.5
and 0.7 suggests that variables can be considered
moderately correlated, whilst correlation coefficients
between 0.3 and 0.5 indicate variables that have a low
correlation [34].
Reliability
In the current study, we evaluated one type of reliability,
internal consistency for the MHQ EQ-5D(utility), EQ-
5D (VAS), SF-12 (PCS), SF-12 (MCS) and SF-6D at
baseline. Internal consistency reliability measures the
homogeneity of the items comprising a scale; that is,
whether the items in the same scale measure the same
underlying concept. We used the Cronbach’s alpha (α)
coefficient to express internal consistency. Cronbach’s al-
phas can range from 0 to 1.0, where 1.0 indicates perfect
internal consistency. Generally, consistency is considered
unacceptable for α <0.5, poor for 0.6 > α ≥ 0.5, question-
able for 0.7 > α ≥ 0.6, acceptable for 0.8 > α ≥ 0.7 and
good for 0.9 > α ≥ 0.8 [32]. Values > 0.90 indicate redun-
dancy [34].
Interpretability
Interpretability is defined as the degree to which one
can assign qualitative meaning to an instrument’s quan-
titative scores or change in scores [26]. Although not
generally considered as a psychometric property, it is an
important characteristic of a measurement instrument.
The interpetability of the different study PROMs was
measured using the minimal important difference
(MID), which reflects the smallest amount of change in
a score that is meaningful to a patient [36].
Responsiveness
Responsiveness considers whether the changes registered
by a measure over time correspond to those expected
based on an external reference measure of health [35].
We made use of two different reference measures to es-
timate the responsiveness of all study PROMs. The first
referent was participant self-rated improvement in their
hands and wrists, which used a seven- point Likert scale
asking whether they had completely recovered, were
much improved, slightly improved, showed no change,
were slightly worse, much worse or vastly worse. These
were collapsed into three categories, namely improved,
no change and worsened for the purposes of these ana-
lyses. The second referent was a self-rated measure of
benefit and satisfaction from trial treatments that
assessed whether participants experienced substantial
benefit, moderate benefit, no benefit, moderate harm or
substantial harm. These were collapsed into three cat-
egories, namely benefit, no benefit and harm for the pur-
pose of these analyses. The estimate of responsiveness
was measured from baseline to 4 months and 4 months
to 12 months for the self-reported hand and wrist func-
tioning measure, and from baseline to 4 months and
baseline to 12 months for the measure of benefit and
satisfaction from trial treatments. A number of statistical
tests were employed for this purpose, including the Ef-
fect Size (ES) and Standardize Response Mean (SRM)
The ES can be defined as the change in mean score di-
vided by the standard deviation of the instrument scores
at baseline. The SRM divides the mean change in score
by the standard deviation of individuals’ change in score.
Changes in both were considered large when the ES and
SRM were greater than 0.8, moderate when they were
between 0.79 and 0.5 and small when they were between
0.49 and 0.2 [26].
Results
A total of 488 participants were recruited into the SA-
RAH trial, 452 (92%) and 438 (89%) of whom were
followed up at 4 and 12 months, respectively. At inclu-
sion in the study there were 76% females and the mean
age was 62.4 years (Table 1).
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Acceptability
Response rates for each outcome measure at baseline,
and 4 and 12 months follow up are reported in Table 1.
Response rates across all study time points ranged from
76.0% (SF-12) to 99.1% (EQ-5D utility). The SF-6D re-
sponse rate (80.1%) was slightly higher than for both SF-
12 subscales (76.0%). At baseline there were no missing
data for the MHQ and the EQ-5D (VAS).
Validity
Table 2 shows the results of the known–groups validity
tests at baseline. Although all differences between low
and high pain troublesomeness scale scores were statisti-
cally significant at the 5% significance level, not all in-
struments discriminated well between patients who had
RA pain versus those who did not (as depicted by the
pain troublesomeness scale). The MHQ and SF-12
(PCS) had large effect sizes (>0.8), while the remainder
of the instruments had medium effect sizes.
Table 3 presents the spearman’s rho correlation coeffi-
cients between the various instruments with all them
being statistically significant at the 1% level of signifi-
cance. Our results suggest that the MHQ correlated
moderately with the SF-6D (ρ = 0.63) and EQ-5D (ρ =
0.65).
Reliability
The internal consistency of the study outcome measures
as estimated by the Cronbach’s alpha coefficient at base-
line (Table 4) was similar across all scales and above the
threshold of 0.70 recommended for broader use in clin-
ical research [10].
Responsiveness and Interpretability
Mean scores for each PROM at baseline and 4 months
follow-up (Table 5) and at 4 and 12 month follow-up
(Appendix 1) are shown for the self-reported hand and
wrist functioning measure, which was used to estimate
responsiveness; changes over time and ES and SRM esti-
mates are also presented.
There was a statistically significant change in MHQ
score for patients reporting improved hand and wrist
functioning (Δ = 13.13) between baseline and 4 months.
This was also the case for the EQ-5D (utility) (Δ = 0.11)
and EQ-5D (VAS) (Δ = 7.5) (Table 5). Minimally import-
ant differences (MID) [interpretability] for each PROM
varied; whilst a meaningful alteration in MHQ score re-
quired a large change over the study period, all other
measures required smaller numerical changes. Table 5
summarises the ESs and SRMs for all measures and
shows that the MHQ score [(ES = 0.79 95% CI: -1.64 to
3.32) and SRM = 0.56 (95% CI: -1.88 to 3.00)] was highly
responsive to capturing improvements in self-reported
hand and wrist function between baseline and 4 months.
ESs and SRMs for EQ-5D (utility) and EQ-5D (VAS)
were larger for the “improved” changes compared to the
other categories. Overall, there were no consistent pat-
terns at detecting changes to hand and wrist functioning
between baseline and 4 months. The same analysis was
repeated for changes between four and 12 months
Table 1 Baseline characteristics and response rates to each outcome measure at each time point (n = 488)
Baseline
(n = 488)
(mean, SD)
4 months
(n = 452)
12 months
(n = 438)
Complete responders (all time points)
Age: mean (SD) 62.4
Sex: % female 76%
Disease duration (years) 10
MHQ 100% (52) 92% 90% 87%
EQ-5D (utility) 99.21% (0.58,0.27) 100% 98.93% 99.10%
EQ-5D (VAS) 100% (66.71,18.75) 92.42% 88.93% 86.27%
SF-12 (PCS) 97% (34,9.67) 87% 84% 76%
SF-12 (MCS) 97% (49,10.99) 87% 84% 76%
SF-6D 99% (0.63,0.14) 89% 86% 81%
Table 2 Known- groups (construct) validity effect sizes for the
pain troublesomeness (baseline data)
Instruments Pain Troublesomeness
Low
(n = 126)
High
(n = 362)
Effect size
(95% CI)
Mean HRQoL score (SD)
MHQ 66.23(13.76)a 45.34 (13.95) 1.51 (1.28,1.73)
EQ-5D (utility) 0.73 (0.20)a 0.53 (0.28) 0.77 (0.57, 0.98)
EQ-5D (VAS) 77.10(15.67)a 63.09(18.41) 0.79 (0.58,0.99)
SF-12 (PCS) 40.70(9.67)a 31.81(8.57) 0.81 (0.60, 1.02
SF-12 (MCS) 51.99(9.10)a 47.33(11.35) 0.33 (0.13, 0.54)
SF-6D 0.71(0.13)a 0.61(0.13) 0.78 (0.57, 0.99)
Statistically significant differences betweena Low/ High score of pain
troublesomeness (2 sample t-test). Effect size is calculated as the difference in
means scores divided by the pool standard deviations. Effect size values for
the dichotomous variables are considered small (<0.5), medium (0.5-0.8), or
large (>0.8). Values in bold indicate large effect sizes
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(Appendix 1). Results suggest more consistent patterns
between all instruments with ESs and SRMs indicating
less than moderate responsiveness to capturing improve-
ment and worsening from 4 to 12 months. Estimates
ranged from 0.35 (MHQ) to -0.34 (EQ-5D VAS).
The results for the analyses that used the perceived
benefit/harm measure are summarised in Appendices 2
and 3 for the alternative follow-up periods and suggest
that all instruments show small responsiveness (ES and
SRM < 0.5) to perceived benefit/harm from the treat-
ments between baseline and 4 months. The MHQ score
as highly responsive to assessments of benefit or harm
over the 12 month follow-up period (ES > 0.8].
Discussion
This study compared the psychometric properties of
generic HRQoL measures [EQ-5D (utility), EQ-5D
(VAS), SF-12 (PCS), SF-12 (MCS), SF-6D (utility)] and a
condition-specific (MHQ) PROM in a large sample of
participants with RA of the hand. We examined the ac-
ceptability, construct validity, convergent validity, in-
ternal consistency, interpretability and responsiveness of
these measures, as defined by the COSMIN checklist
[26] and the checklist of assessment criteria published
by Brazier and colleagues [27]. The reliability and valid-
ity of the MHQ has previously been established [13].
This study is the first to estimate the validity of the
MHQ against an objective measures of pain trouble-
someness. It further compared the MHQ with generic
HRQoL instruments (EQ-5D, SF-12, SF-6D) to under-
stand the strengths and weaknesses of each of these in-
struments in studies of RA of the hand.
High response rates to all measures included in the
study, particularly for the EQ-5D, indicate the high ac-
ceptance of these instruments, by the individuals who
completed and responded to the questionnaires, and
their suitability for self-administration. The high re-
sponse rates over the course of the SARAH study were
achieved through completing measures face to face at a
research clinic and also through follow-up mechanisms
that included reminders sent to study participants by
post or by telephone. The order in which measures were
presented in the self-completion patient questionnaires
(MHQ, EQ-5D, SF-12) might have influenced the re-
sponse rates. Our findings from analyses of construct
validity generally support the ability of all the measures
used to discriminate between different levels of RA se-
verity of the hands. Mean HRQoL or utility scores for all
measures were significantly different between partici-
pants experiencing differing severity of RA pain. This
finding is not in line with the study by Marra et al. [9],
which found that of the Health Utilities Index 2 and 3
(HUI2, HUI3), EQ-5D, SF-6D, RA Quality of Life Ques-
tionnaire (RAQoL) and the Health Assessment Ques-
tionnaire (HAQ) only EQ-5D and SF-6D scores
significantly differed by level of RA severity. Strong asso-
ciations were observed in our study between the MHQ
score and RA pain severity, followed in strength of
Table 3 Convergent (discriminant)validity. Mutitrait-multimethod (MTMM) correlation matrix illustrating the correlation of the differ-
ent measures at baseline, missing data excluded pairwise for each comparison (n = 488)
MHQ (overall) MHQ (hand function both) EQ-5D (utility) EQ-5D (VAS) SF-12 (PCS) SF-12 (MCS) SF-6D
MHQ 1
EQ-5D (utility) 0.65 0.48 1
EQ-5D (VAS) 0. 51 0. 42 0. 57 1
SF-12 (PCS) 0. 59 0. 46 0. 61 0. 56 1
SF-12 (MCS) 0. 32 0. 23 0. 42 0. 40 0. 25 1
SF-6D 0.63 0.42 0.68 0.58 0.70 0.67 1
Correlation coefficients (spearman’s rho). All correlations are statistical significance (p < 0.01). Values in bold indicate correlations expected to exceed 0.7
(convergent validity)
Table 4 Average inter-item correlation and Cronbach’s Alpha scores for study outcome measures at baseline
Average Inter- item correlation Cronbach’s Alphas Internal Consistency
MHQ 0.45 0.83 Good
EQ-5D (utility) 0.47 0.84 Good
EQ-5D (VAS) 0.48 0.84 Good
SF-12 (PCS) 0.46 0.84 Good
SF-12 (MCS) 0.52 0.87 Good
SF-6D 0.44 0.83 Good
Internal consistency is considered unacceptable for α <0.5, poor for 0.6 > α ≥ 0.5, questionable for 0.7 > α ≥ 0.6, acceptable for 0.8 > α ≥ 0.7, good for 0.9 > α ≥ 0.8
and excellent for α ≥ 0.9 [32, 34]
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association with RA pain severity by the EQ-5D
(utility) and the SF-6D. In addition, our results sug-
gest that the MHQ was highly responsive to assess-
ments of benefit or harm over the 12 month follow-
up period within the SARAH trial. Adams et al. [36]
previously concluded that the EQ-5D is more re-
sponsive to deterioration in RA pain than the SF-6D
and the SF-6D is more responsive to RA improve-
ment than the EQ-5D. The physical component of
the SF-12 had more consistent construct validity in
our study than the mental health component of the
measure, which is in agreement with the findings of
Kosinskli et al. [37] in their validation study of the
SF-36. Our findings with regards to the ability of the
physical and mental health components of the SF-12
to discriminate between RA pain severity are also in
agreement with the study by Linde et al. [38].
Our convergent validity analysis indicated that the
MHQ score correlates most strongly with the EQ-5D
(utility) score. The low level of correlation found be-
tween the SF-12 (MCS) and MHQ, and between the
remaining PROMs, indicates that their respective
constructs may be non-overlapping. The physical com-
ponent of the SF-12 demonstrated the highest degree of
inter-relatedness, especially with the EQ-5D. All mea-
sures under investigation displayed acceptable internal
consistency as measured by Cronbach’s alpha values
(>0.70).
The large ESs and SRMs for the MHQ indicates
that this measure is very responsive at detecting
changes in self-reported hand and wrist function-
ing; its responsiveness was followed by that for the
EQ-5D (utility), SF-12 (PCS) and SF-6D. The SF-12
(MCS) could only moderately detect such changes.
Overall, the measures, particularly the MHQ and
EQ-5D, were more responsive at detecting improve-
ment in external measures of health rather than
worsening or no change. Our condition-specific in-
strument (MHQ) performed better at detecting
patient-reported changes in external measures of
health compared to the generic measures. This find-
ing contradicts Linde and colleagues [38] who found
no superiority in responsiveness of RA clinical mea-
sures (Rheumatoid Arthritis Quality of Life Scale
Table 5 Responsiveness of measures over time to self-reported hand and wrist functioning; baseline to 4 months
n T0 T4 Δ (95% CI) SRM (95% CI) ES (95% CI)
MHQ
Improved 177 51.66 64.79 13.13 (9.67 to 16.58) 0.56 (-1.88 to 3.00) 0.79 (-1.64 to 3.23)
No change 150 54.15 56.97 2.82 (-0.96 to 6.59) 0.12 (-2.55 to 2.79) 0.16 (-2.51 to 2.83)
Worsened 113 47.2 45.37 -1.83 (-6.03 to 2.36) -0.08 (-3.05 to 2.89) -0.11 (-3.08 to 2.85)
EQ-5D (utility)
Improved 177 0.58 0.69 0.11 (0.06 to 0.16) 0.31 (0.27 to 0.36) 0.44 (0.41 to 0.49)
No change 150 0.61 0.62 0.01 (-0.04 to 0.06) 0.03 (-0.01 to 0.07) 0.04 (0.00 to 0.08)
Worsened 113 0.55 0.48 -0.07 (-0.15 to 0.01) -0.16 (-0.22 to -0.11) -0.23 (-0.28 to -0.18)
EQ-5D (VAS)
Improved 177 68.28 75.78 7.5 (3.9 to 11.10) 0.31 (-2.38 to 3.00) 0.43 (-2.26 to 3.13)
No change 150 68.99 67.46 -1.53 (-5.67 to 2.62) -0.05 (-2.87 to 2.76) -0.08 (-2.90 to 2.73)
Worsened 113 64.92 60.43 -4.49 (-9.50 to 0.52) -0.16 (-3.81 to 3.48) -0.23 (-3.88 to 3.41)
SF-12 (PCS)
Improved 177 34.59 36.63 2.04 (-0.5 to 4.58) 0.12 (-1.44 to 1.67) 0.19 (-1.71 to 2.11)
No change 150 33.13 34.48 1.35 (-1.31 to 4.01) 0.081 (-1.89 to 2.05) 0.11 (-1.85 to 2.08)
Worsened 113 31.43 30.44 -0.99 (-3.83 to 1.86) -0.06 (-2.04 to 1.91) -0.09 (-2.06 to 1.88)
SF-12 (MCS)
Improved 177 48.98 48.12 -0.86 (-3.69 to 1.98) -0.04 (-1.75 to 1.66) -0.06 (-1.77 to 1.65)
No change 150 46.52 49.29 2.77 (-0.44 to 5.98) 0.13 (-2.34 to 2.62) 0.19 (-2.29 to 2.68)
Worsened 113 46.02 44.01 -2.01 (-5.76 to 1.74) -0.09 (-2.75 to 2.55) -0.14 (-2.79 to 2.51)
SF-6D
Improved 177 0.65 0.68 0.03 (-0.00 to 0.06) 0.15 (0.12 to 0.16) 0.21 (0.19 to 0.23)
No change 150 0.65 0.65 0 (-0.03 to 0.03) 0 (-0.02 to 0.02) 0 (-0.02 to 0.02)
Worsened 113 0.6 0.59 -0.01 (-0.05 to 0.03) -0.05 (-0.07 to -0.02) -0.07 (-0.09 to -0.04)
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(RAQoL) and Health Assessment Questionnaire
(HAQ)) compared to the EQ-5D.
A possible weakness of this study is that due to
data limitations, we were unable to assess the criter-
ion validity, content validity and test-retest reliability
of the measures. Also, some of the limitations of the
analytical strategy are related to the use of total
scores for many of the PROMs instead of using
weighted methods (through, for example, factor ana-
lysis or Item Response Theory) [39].
Despite the study limitations, it should help to in-
form clinical researchers and health economists in
this field in their selection of PROMs for use in
their clinical and health economic evaluations. More
specifically, the precision of trials in the context of
RA where health outcomes are measured through a
single instrument will be enhanced by evidence sur-
rounding the psychometric properties of the alterna-
tive outcome measures evaluated in our study.
Conclusions
In conclusion, the instruments evaluated in this study dis-
played varying psychometric properties in the context of
RA of the hand. Our results extend beyond those of Harri-
son et al. [40], who previously proposed that at least one
measure of HRQoL is included in studies of inflammatory
arthritis. Our study revealed that of the study measures,
the MHQ was most responsive at detecting change in in-
dicators of RA pain severity, whilst the EQ-5D offered ad-
vantages over the SF-12 and its preference-based
derivative (SF-6D) with respect to some psychometric
properties. However, the selection of a preferred instru-
ment in evaluative studies should ultimately depend on
the relative importance placed on individual psychometric
properties and the importance placed on generation of
health utilities for economic evaluation purposes. Future
studies are also needed to establish the generalizability of
our findings for different hand conditions and different
hand practices.
Table 6 Responsiveness of measures over time to self-reported hand and wrist functioning; 4 to 12 months
n T4 T12 Δ (95% CI) SRM (95% CI) ES (95% CI)
MHQ
Improved 177 64.79 61.04 -3.75 (-6.19 to -1.31) -0.13 (-2.57 to 2.31) -0.19 (-2.63 to 2.25)
No change 150 56.97 58.53 1.56 (-1.11 to 4.23) 0.06 (-2.61 to 2.73) 0.09 (-2.58 to 2.76)
Worsened 113 45.37 46.22 0.85 (-2.12 to 3.82) 0.04 (-18.9 to 19.65) 0.05 (-2.92 to 3.02)
EQ-5D (utility)
Improved 177 0.69 0.67 -0.02 (-0.05 to 0.01_ -0.06 (-0.09 to -0.03) -0.09 (-0.12 to -0.06)
No change 150 0.62 0.64 0.02 (-0.02 to 0.06) 0.06 (0.03 to 0.10) 0.091 (0.05 to 0.13)
Worsened 113 0.48 0.57 0.09 (0.03 to 0.15) 0.22 (0.16 to 0.28) 0.31 (0.25 to 0.37)
EQ-5D (VAS)
Improved 177 75.78 68.92 -6.86 (-9.25 to -4.47) -0.24 (-2.63 to 2.14) -0.35 (-2.74 to 2.03)
No change 150 67.46 68.55 1.09 (-1.95 to 4.13) 0.04 (-2.99 to 3.08) 0.06 (-2.98 to 3.10)
Worsened 113 60.43 58.66 -1.77 (-5.21 to 1.67) -0.06 (-3.49 to 3.75) -0.08 (-3.52 to 3.35)
SF-12 (PCS)
Improved 177 36.63 34.19 -2.44 (-4.45 to -0.43) -0.12 (-2.13 to 1.88) -0.17 (-2.18 to 1.83)
No change 150 34.48 35.22 0.74 (-1.04 to 2.52) 0.05 (-1.74 to 1.83) 0.06 (-1.72 to 1.85)
Worsened 113 30.44 29.64 -0.8 (-2.84 to 1.24) -0.05 (-2.09 to 1.99) -0.07 (-2.11 to 1.97)
SF-12 (MCS)
Improved 177 48.12 47.16 -0.96 (-3.22 to 1.31) -0.04 (-2.31 to 2.22) -0.17 (-2.17 to 1.84)
No change 150 49.29 50.81 1.52 (-0.50 to 3.54) 0.09 (-1.93 to 2.11) 0.13 (-1.89 to 2.15)
Worsened 113 44 44.96 0.96 (-1.69 to 3.61) 0.04 (-2.61 to 2.69) 0.06 (-2.59 to 2.72)
SF-6D
Improved 177 0.68 0.64 -0.04 (-0.06 to -0.02) -0.15 (-0.17 to -0.13) -0.22 (-0.24 to -0.19)
No change 150 0.65 0.67 0.02 (0.00 to 0.04) 0.18 (0.09 to 0.13) 0.15 (0.13 to 0.18)
Worsened 113 0.59 0.6 0.01 (-0.02 to 0.04) 0.05 (0.02 to 0.07) 0.06 (0.04 to 0.09)
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Appendix 2
Table 7 Responsiveness of measures over time to perceived benefit/harm; baseline to 4 months
n T0 T4 Δ (95% CI) SRM (95% CI) ES (95% CI)
MHQ
Benefit 303 51.91 57.86 5.95 (2.75 to 9.15) 0.21 (-1.70 to 3.12) 0.29 (-1.61 to 2.21)
No benefit 116 49.34 49.14 -0.2 (-3.46 to 3.06) -0.01 (-2.98 to 2.96) -0.02 (-2.98 to 2.95)
Harm 11 45.93 48.37 2.44 (-11.61 to 16.48) 0.10 (-7.40 to 7.61) 0.14 (-7.36 to 7.65)
EQ-5D (utility)
Benefit 303 0.59 0.63 0.04 (0.00 to 0.08) 0.11 (0.08 to 0.14) 0.15 (0.13 to 0.18)
No benefit 116 0.59 0.57 -0.02 (-0.09 to 0.05) -0.05 (-0.09 to 0.00) -0.07 (-0.12 to -0.02)
Harm 11 0.55 0.59 0.04 (-0.23 to 0.31) 0.09 (-0.13 to 0.31) 0.13 (-0.09 to 0.35)
EQ-5D (VAS)
Benefit 303 68.92 71.99 3.07 (0.32 to 5.82) 0.13 (-1.85 to 2.10) 0.18 (-1.80 to 2.15)
No benefit 116 65.77 63.09 -2.68 (-7.93 to 2.57) -0.09 (-3.72 to 3.53) -0.13 (-3.75 to 4.49)
Harm 11 61.18 61.81 0.63 (-18.12 to 19.38) 0.02 (-15.19 to 15.23) 0.03 (-15.18 to 15.23)
SF-12 (PCS)
Benefit 303 34.02 35.27 1.25 (-0.64 to 3.14) 0.07 (-1.16 to 1.32) 0.11 (-1.14 to 1.35)
No benefit 116 32.85 33.59 0.74 (-1.95 to 3.43) 0.05 (-1.94 to 2.04) 0.07 (-1.92 to 2.06)
Harm 11 27.23 29.06 1.83 (-11.40 to 15.06) 0.08 (-9.47 to 9.63) 0.12 (-9.43 to 9.66)
SF-12 (MCS)
Benefit 303 48.07 47.85 -0.22 (-2.39 to 1.96) -0.01 (-1.46 to 1.44) -0.02 (-1.47 to 1.43)
No benefit 116 47.45 47.93 0.48 (-2.89 to 3.85) 0.03 (-2.45 to 2.50) 0.04 (-2.43 to 2.51)
Harm 11 35.9 33.66 -2.24 (-19.75 to 15.27) -0.08 (-12.62 to 12.46) -0.11 (-12.64 to 12.43)
SF-6D
Benefit 303 0.65 0.66 0.01 (-0.01 to 0.03) 0.05 (0.03 to 0.06) 0.06 (0.05 to 0.08)
No benefit 116 0.63 0.64 0.01 (-0.03 to 0.05) 0.05 (0.02 to 0.08) 0.07 (0.04 to 0.10)
Harm 11 0.61 0.52 -0.09 (-0.24 to 0.06) -0.36 (-0.45 to -0.27) -0.51 (-0.06 to -0.04)
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Table 8 Responsiveness of measures over time to perceived benefit/harm; baseline to 12 months
n T0 T12 Δ (95% CI) SRM (95% CI) ES (95% CI)
MHQ
Benefit 276 51.15 57.83 6.68 (3.75 to 9.61) 0.26 (-1.74 to 2.27) 1.03 (-0.97 to 3.04)
No benefit 110 50.86 49.15 -1.71 (-6.21 to 2.79) -0.07 (-3.18 to 3.05) 1.02 (-2.09 to 4.14
Harm 6 46.33 46.34 0.01 (-20.65 to 20.67) 0.00 (-11.13 to 11.13) 1.22 (-9.91 to 12.35)
EQ-5D (utility)
Benefit 276 0.59 0.61 0.06 (0.02 to 0.10) 0.17 (0.14 to 0.19) 0.24 (0.20to 0.26)
No benefit 110 0.59 0.57 -0.03 (-0.09 to 0.03) -0.09 (-0.14 to -0.05) -0.13 (-0.17 to -0.08)
Harm 6 0.53 0.54 -0.05 (-0.03 to 0.23) -0.15 (-0.25 to -0.03) -0.22 (-0.34 to -0.09)
EQ-5D (VAS)
Benefit 276 69.57 67.92 -1.65 (-3.67 to 0.37) -0.06 (-2.08 to 1.96) -0.08 (-2.10 to 1.94)
No benefit 110 64.89 61.3 -3.59 (- 7.08 to -0.09) -0.13 (-3.63 to 3.35) -0.19 (-3.68 to 3.30)
Harm 6 60.16 57 -3.16 (-19.83 to 13.56) -0.11 (-16.83 to 16.61) -0.15 (-16.87 to 18.42)
SF-12 (PCS)
Benefit 276 34.44 32.93 -1.51 (-2.77 to -0.24) -0.08 (-1.35 to 1.18) -0.12 (-1.38 to 1.15)
No benefit 110 31.79 31 -0.79 (-2.86 to 1.28) -0.15 (-2.13 to 2.02) -0.08 (-2.15 to 1.99)
Harm 6 24.84 36.08 11.24 (-0.27 to 22.75) 0.67 (-10.84 to 12.19) 0.99 (-10.52 to 12.51)
SF-12 (MCS)
Benefit 276 48.26 47.31 -0.95 (-2.44 to 0.54) -0.05 (-1.54 to 1.45) -0.06 (-1.56 to 1.42)
No benefit 110 48.04 49.44 1.4 (-1.06 to 3.86) 0.08 (-2.38 to 2.54) 0.12 (-2.34 to 2.57)
Harm 6 32.7 37.74 5.04 (-11.59 to 21.67) 0.21 (-16.42 to 16.84) 0.31 (-16.32 to 16.95)
SF-6D
Benefit 276 0.64 0.63 -0.01 (-0.03 to 0.01) -0.04 (-0.06 to -0.02) -0.06 (-0.07 to -0.04)
No benefit 110 0.63 0.63 0 (-0.02 to 0.02) 0 (-0.02 to 0.02) 0 (-0.02 to 0.02)
Harm 6 0.58 0.58 0 (-0.06 to 0.06) 0 (-0.06 to 0.06) 0 (-0.06 to 0.06)
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